Monday, June 6, 2016

BRIEF-Immunomedics says sacituzumab govitecan demonstrates efficacy, safety in patients

* Sacituzumab govitecan (IMMU-132) demonstrates efficacy and

safety in non-small-cell lung cancer patients with multiple

prior treatments, including immuno-oncology

Source text for Eikon:

Further company coverage:

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)